2019
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Kim I, Kim S, Srivastava A, Saraiya B, Mayer T, Kim W, Kim I. Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer. BMC Urology 2019, 19: 33. PMID: 31060606, PMCID: PMC6501301, DOI: 10.1186/s12894-019-0453-9.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerDDR pathway alterationProstate cancerPathway alterationsMetastatic castration-resistant prostate cancerSerum prostate-specific antigenHigh-risk diseaseMetastatic prostate cancerLower overall survivalPathway gene mutationsProstate-specific antigenPotential therapeutic targetUnited States National Cancer InstituteNational Cancer InstituteCRPC patientsCancer Genome AtlasOverall survivalSimilar incidenceTumor stageUnivariate analysisCancer InstituteTherapeutic targetSpecific antigenPARP inhibitorsPathway status
2015
A robust blood gene expression-based prognostic model for castration-resistant prostate cancer
Wang L, Gong Y, Chippada-Venkata U, Heck M, Retz M, Nawroth R, Galsky M, Tsao C, Schadt E, de Bono J, Olmos D, Zhu J, Oh W. A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. BMC Medicine 2015, 13: 201. PMID: 26297150, PMCID: PMC4546313, DOI: 10.1186/s12916-015-0442-0.Peer-Reviewed Original ResearchConceptsFour-gene modelCRPC patientsProstate cancerClinical parametersBackgroundCastration-resistant prostate cancerCastration-resistant prostate cancerSurvival of CRPC patientsGene-expression-based prognostic modelsBiomarker modelProstate cancer lethalityImmune cell componentsGene modelsGenes associated with cancer progressionMRNA profilesIntegrative genomic analysisWorse survivalPrognostic improvementBiological processesClinical predictorsAssociated with wide variationsCancer lethalityMyeloid cellsIntegrative genomics approachPrognostic powerCRPC
2014
A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer
Courtney K, Manola J, Elfiky A, Ross R, Oh W, Yap J, Van den Abbeele A, Ryan C, Beer T, Loda M, Priolo C, Kantoff P, Taplin M. A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer 2014, 13: 113-123. PMID: 25450031, PMCID: PMC4418946, DOI: 10.1016/j.clgc.2014.08.007.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorDocetaxelDrug Administration ScheduleEverolimusFluorodeoxyglucose F18HumansMaleMaximum Tolerated DoseMiddle AgedPositron-Emission TomographyProstatic Neoplasms, Castration-ResistantTaxoidsTreatment OutcomeConceptsProstate-specific antigenPartial metabolic responseFDG-PETMTOR inhibitorsFDG-PET/computed tomography scansProstate-specific antigen reductionTolerability of combination therapyCastration-resistant prostate cancerActivation of AKT-mTOR signalingFDG-PET responseLevels of everolimusStable metabolic diseaseResponse to everolimusPhase I studyPhase I trialMetabolic diseasesProgressive metabolic diseaseConcentrations of everolimusAkt-mTOR signalingCRPC patientsCombination therapyI trialProstate cancerTomography scanPatient cohort
2010
Platinum Agents in Prostate Cancer
Brick A, Niu J, Huang J, Oh W. Platinum Agents in Prostate Cancer. 2010, 153-161. DOI: 10.1007/978-1-60327-829-4_14.Peer-Reviewed Original ResearchCastration-resistant prostate cancerPlatinum agentsSurvival benefitProstate cancerMetastatic castration-resistant prostate cancerProgression-free survival benefitStandard first-line treatmentMetastatic CRPC patientsSecond-line settingSecond-line treatmentPhase III trialsFirst-line treatmentCRPC patientsDocetaxel chemotherapyNeuroendocrine differentiationIII trialsPlatinum analogsDisease progressionPlatinum drugsModerate responsePrednisoneSatraplatinCancerTrialsTreatmentProstate Cancer, Comorbidity, and Participation in Randomized Controlled Trials of Therapy
Chao H, Mayer T, Concato J, Rose M, Uchio E, Kelly K. Prostate Cancer, Comorbidity, and Participation in Randomized Controlled Trials of Therapy. Journal Of Investigative Medicine 2010, 58: 566-568. DOI: 10.2310/jim.0b013e3181cf9002.Peer-Reviewed Original ResearchCastrate-resistant prostate cancerPhase 3 RCTsProstate cancerClinical settingPhase 3 clinical trialsVeterans Affairs Connecticut Healthcare SystemGeneral oncology practiceAbnormal laboratory valuesPopulation of patientsRandomized Controlled TrialsComplete medical recordsSerious medical conditionProportion of menBackground RandomizedChemotherapy regimensCRPC patientsControlled TrialsMedical recordsClinical trialsOncology practiceInclusion criteriaLaboratory valuesCardiac diseaseMedical conditionsClinical care
2009
Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial
Sartor A, Petrylak D, Sternberg C, Witjes F, Halabi S, Berry W, Petrone M, McKearn T, Noursalehi M, George M. Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial. Journal Of Clinical Oncology 2009, 27: 5148-5148. DOI: 10.1200/jco.2009.27.15_suppl.5148.Peer-Reviewed Original ResearchCastration-refractory prostate cancerOverall survivalPain progressionBaseline painSPARC trialChemotherapy trialsPPI scoresMetastatic castration-refractory prostate cancerFirst-line chemotherapy trialsMcGill-Melzack Pain QuestionnaireFirst-line docetaxelMedian overall survivalNarcotic analgesic usePre-treated patientsDaily pain intensityImportant prognostic indicatorEffect of painUse of painShortened overall survivalAnalgesic useCRPC patientsMedian survivalPain intensityPain QuestionnairePrognostic indicatorCorrelation of progression-free survival (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) who failed first-line chemotherapy: Results from the SPARC Trial
Halabi S, Sartor O, Petrylak D, Sternberg C, Witjes J, Noursalehi M, McKearn T, George M. Correlation of progression-free survival (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) who failed first-line chemotherapy: Results from the SPARC Trial. Journal Of Clinical Oncology 2009, 27: 5150-5150. DOI: 10.1200/jco.2009.27.15_suppl.5150.Peer-Reviewed Original ResearchProgression-free survivalCastration-resistant prostate cancerFirst-line chemotherapyOverall survivalMetastatic castration-resistant prostate cancerChemotherapy-naïve patientsDouble-blind trialDate of randomizationMedian survival timePredictors of OSProportional hazards modelType of progressionSPARC trialLine chemotherapyCRPC patientsNaïve patientsFirst progressionTau measuresProstate cancerLandmark analysisSurvival timeTreatment groupsHazards modelStratification factorsClinical relevance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply